Gilead Sciences, Inc. Overview
Pro stress-test →Gilead Sciences is a biopharmaceutical company that has pursued breakthroughs in medicine for more than three decades, committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. For 2025, Gilead achieved total revenues of $29.4 billion, with product sales excluding Veklury growing 4% to $28.0 billion.
Strategic Profile
Pro stress-test →Gilead's HIV product sales reached $20.8 billion in 2025 (up 6%), driven by flagship treatments Biktarvy ($14.3B, +7%) and Descovy ($2.8B, +31%), establishing the company as a leading HIV care provider. The company is executing a multi-year strategy to drive growth across virology, oncology, and inflammation with planned $32 billion U.S. investment through 2030.
Competitive Landscape
Pro stress-test →Gilead operates as a leading biopharmaceutical company in HIV treatment and prevention. Primary competitors include Merck (HIV antiretrovirals), ViiV Healthcare/GSK (Biktarvy alternatives), Johnson & Johnson (HIV/oncology), and AbbVie (virology/oncology). Gilead maintains competitive advantages through its established HIV franchise, recent approvals of innovative prevention therapies like Yeztugo, and expanding oncology pipeline.
Industry Context
Gilead Sciences, Inc. operates in Biopharmaceutical - HIV, Virology, Oncology, Immunology.
Key facts
Founded: 1987 · Headquarters: Foster City, US · Revenue: $29.4B